STOCK TITAN

Immutep Limited - $IMMP STOCK NEWS

Welcome to our dedicated page for Immutep news (Ticker: $IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.

Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.

At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.

In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.

Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.

For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.

Rhea-AI Summary

Immutep has announced the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer, raising approximately A$89.6 million. The offer price was A$0.38 per new share, and it saw strong support from institutional investors, achieving a 100% take-up rate. The total expected to be raised by the offer is A$100.2 million, including the upcoming retail entitlement offer set to open on June 7, 2024. New shares are expected to be issued and commence trading by mid-June 2024. The funds raised will support Immutep's late-stage clinical programs in lung, breast, and head and neck cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.08%
Tags
none
-
Rhea-AI Summary

Immutep announced a Phase III clinical trial collaboration with MSD to evaluate eftilagimod alfa (efti) combined with KEYTRUDA® (pembrolizumab) and chemotherapy in treating first-line metastatic non-small cell lung cancer (NSCLC).

The TACTI-004 trial will involve 750 patients regardless of PD-L1 expression. Under the agreement, Immutep will conduct the trial, and MSD will supply KEYTRUDA. Immutep retains commercial rights to efti.

Past trials have shown promising efficacy and safety of the combination therapy. This trial aims to confirm these benefits and potentially set a new standard of care for NSCLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Immutep presented promising data from the safety lead-in phase of their AIPAC-003 Phase II/III trial at the ESMO Breast Cancer Congress 2024. The trial, combining 90mg efti with paclitaxel, showed a 50% overall response rate and a 100% disease control rate in six metastatic breast cancer patients. Notably, one patient achieved a complete response which is ongoing with efti monotherapy. The combination has been well tolerated with no severe adverse events. Higher efti concentrations were observed, remaining pharmacologically active up to 96 hours post-administration. The randomized Phase II portion continues, with more data expected in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
Rhea-AI Summary

Immutep has reported positive initial clinical data from the Phase II EFTISARC-NEO trial, combining efti with radiotherapy and pembrolizumab in soft tissue sarcoma patients. The trial showed very good pathologic responses rarely seen with standard therapies, with 67% of patients having near-complete responses. This novel triple combination was well tolerated, with no new safety concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
-
Rhea-AI Summary

Immutep provides an update on its product candidates development, including positive clinical data in breast cancer and head and neck squamous cell carcinoma patients, progress in various phase II and III trials, appointment of a new director, and financial summary. The Company remains well-funded with a cash balance of approximately $95.4 million as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
-
Rhea-AI Summary
Immutep announces positive preliminary topline results from Cohort B of the TACTI-003 Phase IIb trial, showing a 26.9% response rate in first-line head and neck squamous cell carcinoma patients who do not express PD-L1. The investigational combination of eftilagimod alpha and KEYTRUDA® demonstrates promising overall response and disease control rates, expanding treatment options for this challenging cancer type. The data suggests that efti's unique activation of antigen-presenting cells enhances the immune system's response to anti-PD-(L)1 therapies, potentially benefiting patients with negative PD-L1 expression. The study continues to collect and analyze data, with full results expected in H1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
Rhea-AI Summary
Immutep partners with CHDR for a Phase I trial of IMP761, a LAG-3 agonist antibody to treat autoimmune diseases. The trial will utilize a unique challenge model to assess pharmacological activity. IMP761 aims to restore immune system balance and target autoimmune disease causes. The study is set to begin in mid-CY2024 with 49 healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
management clinical trial
-
Rhea-AI Summary
Immutep receives positive feedback from the Spanish Medicines Agency for the upcoming TACTI-004 registrational trial in metastatic non-small cell lung cancer. The AEMPS supports Immutep moving into a registrational trial in 1L NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Immutep Limited announces positive safety and initial efficacy data from the AIPAC-003 trial, showing encouraging results in metastatic breast cancer patients. The combination of 90mg efti with paclitaxel is safe and well-tolerated, with a 50% overall response rate and a 100% disease control rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.06%
Tags
Rhea-AI Summary
Immutep Limited (IMMP) reports promising clinical data from various phase II and III trials, including strong overall survival and response rates in non-small cell lung cancer patients. The company is well-financed with a cash balance of A$103.7 million, providing cash runway to early CY 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is Immutep Limited?

Immutep Limited is a biotechnology company developing innovative immunotherapy products for cancer and autoimmune diseases.

What products does Immutep specialize in?

Immutep specializes in products based on the LAG-3 immune control mechanism, including IMP321 for cancer chemo-immunotherapy, and other LAG-3 related products like IMP701 and CVac.

What is the LAG-3 immune control mechanism?

The LAG-3 immune control mechanism is crucial for regulating the T cell immune response and is used by Immutep in developing therapies for cancer and autoimmune diseases.

What is IMP321?

IMP321 is a T cell immunostimulatory factor (APC activator) developed by Immutep for cancer chemo-immunotherapy. It has completed Phase II clinical trials.

What are the other key products in Immutep's pipeline?

Other key products include IMP701, a blocking anti-LAG-3 antibody for cancer, and CVac, a personalized immunocellular therapeutic for epithelial cancer.

With which markets is Immutep affiliated?

Immutep is listed on the Australian Stock Exchange and the Nasdaq Global Market in the U.S.

Where is Immutep headquartered?

Immutep is headquartered in Australia.

What are Immutep's key partnerships?

Immutep collaborates with large pharmaceutical companies to develop and bring its products to market.

How does Immutep generate revenue?

Immutep generates the majority of its revenue from the sale of its biotechnology products.

Why should investors consider Immutep?

Investors should consider Immutep for its cutting-edge research, promising clinical advancements in immunotherapy, and strategic partnerships.

Immutep Limited

Nasdaq:IMMP

IMMP Rankings

IMMP Stock Data

328.75M
1.05B
0.01%
2.47%
3.14%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Sydney